Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi.
Authors:
- R DietzeRDR Dietze
- S F CarvalhoSCS F Carvalho
- L C ValliLVL C Valli
- J BermanJBJ Berman
- T BrewerTBT Brewer
- W MilhousWMW Milhous
- J SanchezJSJ Sanchez
- B SchusterBSB Schuster
- M GroglMGM Grogl
- 1 December 2001
- journal article
- clinical trial
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 65 (6) , 685-689